Suppr超能文献

一种对分子大小和结合亲和力对肿瘤靶向影响的建模分析。

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.

机构信息

Department of Biological Engineering, Massachusetts Institute of Technology, Building E19-551, 50 Ames Street, Cambridge, MA 02139, USA.

出版信息

Mol Cancer Ther. 2009 Oct;8(10):2861-71. doi: 10.1158/1535-7163.MCT-09-0195.

Abstract

A diverse array of tumor targeting agents ranging in size from peptides to nanoparticles is currently under development for applications in cancer imaging and therapy. However, it remains largely unclear how size differences among these molecules influence their targeting properties. Here, we develop a simple, mechanistic model that can be used to understand and predict the complex interplay between molecular size, affinity, and tumor uptake. Empirical relationships between molecular radius and capillary permeability, interstitial diffusivity, available volume fraction, and plasma clearance were obtained using data in the literature. These relationships were incorporated into a compartmental model of tumor targeting using MATLAB to predict the magnitude, specificity, time dependence, and affinity dependence of tumor uptake for molecules across a broad size spectrum. In the typical size range for proteins, the model uncovers a complex trend in which intermediate-sized targeting agents (MW, approximately 25 kDa) have the lowest tumor uptake, whereas higher tumor uptake levels are achieved by smaller and larger agents. Small peptides accumulate rapidly in the tumor but require high affinity to be retained, whereas larger proteins can achieve similar retention with >100-fold weaker binding. For molecules in the size range of liposomes, the model predicts that antigen targeting will not significantly increase tumor uptake relative to untargeted molecules. All model predictions are shown to be consistent with experimental observations from published targeting studies. The results and techniques have implications for drug development, imaging, and therapeutic dosing.

摘要

目前,正在开发各种大小不一的肿瘤靶向药物,从肽到纳米颗粒不等,用于癌症成像和治疗。然而,这些分子的大小差异如何影响它们的靶向特性,在很大程度上仍不清楚。在这里,我们开发了一种简单的、基于机制的模型,可以用来理解和预测分子大小、亲和力和肿瘤摄取之间复杂的相互作用。使用文献中的数据获得了分子半径与毛细血管通透性、间质扩散率、可用体积分数和血浆清除率之间的经验关系。这些关系被纳入到使用 MATLAB 进行肿瘤靶向的隔室模型中,以预测分子在广泛的大小范围内对肿瘤的摄取的幅度、特异性、时间依赖性和亲和力依赖性。在典型的蛋白质大小范围内,该模型揭示了一种复杂的趋势,即中等大小的靶向剂(MW,约 25 kDa)具有最低的肿瘤摄取,而较小和较大的靶向剂则具有更高的肿瘤摄取水平。小肽在肿瘤中迅速积累,但需要高亲和力才能保留,而较大的蛋白质可以用 >100 倍弱的结合来实现类似的保留。对于脂质体大小范围内的分子,该模型预测抗原靶向相对于未靶向分子不会显著增加肿瘤摄取。所有模型预测都与来自已发表的靶向研究的实验观察结果一致。该结果和技术对药物开发、成像和治疗剂量具有重要意义。

相似文献

1
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.
Mol Cancer Ther. 2009 Oct;8(10):2861-71. doi: 10.1158/1535-7163.MCT-09-0195.
2
Size-Dependent EPR Effect of Polymeric Nanoparticles on Tumor Targeting.
Adv Healthc Mater. 2020 Jan;9(1):e1901223. doi: 10.1002/adhm.201901223. Epub 2019 Dec 3.
4
Influence of the duration of intravenous drug administration on tumor uptake.
Front Oncol. 2013 Jul 25;3:192. doi: 10.3389/fonc.2013.00192. eCollection 2013.
5
Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.
Cancer Res. 2010 Feb 15;70(4):1595-605. doi: 10.1158/0008-5472.CAN-09-2724. Epub 2010 Feb 2.
7
Side-by-Side Comparison of Commonly Used Biomolecules That Differ in Size and Affinity on Tumor Uptake and Internalization.
PLoS One. 2015 Apr 22;10(4):e0124440. doi: 10.1371/journal.pone.0124440. eCollection 2015.
8
Practical theoretic guidance for the design of tumor-targeting agents.
Methods Enzymol. 2012;503:255-68. doi: 10.1016/B978-0-12-396962-0.00010-0.
10
Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport.
J Control Release. 2018 Jun 10;279:126-135. doi: 10.1016/j.jconrel.2018.04.013. Epub 2018 Apr 11.

引用本文的文献

1
Past, present and future of drug conjugates for cancer therapy.
Nat Cancer. 2025 Sep 11. doi: 10.1038/s43018-025-01042-w.
3
Modernizing Preclinical Drug Development: The Role of New Approach Methodologies.
ACS Pharmacol Transl Sci. 2025 May 29;8(6):1513-1525. doi: 10.1021/acsptsci.5c00162. eCollection 2025 Jun 13.
6
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside.
Mol Cancer. 2025 Jun 9;24(1):169. doi: 10.1186/s12943-025-02368-w.
7
Affibodies as valuable tool to prevent βm aggregation under lysosomal-like conditions.
Biol Direct. 2025 Jun 6;20(1):67. doi: 10.1186/s13062-025-00659-2.
8
Target-Mediated Drug Disposition (TMDD) Revisited: High Versus Low-Affinity Approximations of the TMDD Model.
CPT Pharmacometrics Syst Pharmacol. 2025 Jul;14(7):1262-1272. doi: 10.1002/psp4.70048. Epub 2025 May 27.
10
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates.
J Pharmacokinet Pharmacodyn. 2025 May 5;52(3):27. doi: 10.1007/s10928-025-09978-3.

本文引用的文献

1
Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability.
Cancer Immunol Immunother. 2008 Dec;57(12):1879-90. doi: 10.1007/s00262-008-0518-1. Epub 2008 Apr 12.
3
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2586-91. doi: 10.1073/pnas.0711714105. Epub 2008 Feb 13.
4
Factors determining antibody distribution in tumors.
Trends Pharmacol Sci. 2008 Feb;29(2):57-61. doi: 10.1016/j.tips.2007.11.004. Epub 2008 Jan 7.
5
(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Bioconjug Chem. 2007 Nov-Dec;18(6):1956-64. doi: 10.1021/bc7002617. Epub 2007 Oct 19.
6
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54. doi: 10.1073/pnas.0707461104. Epub 2007 Sep 17.
8
99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
Eur J Nucl Med Mol Imaging. 2007 Nov;34(11):1843-53. doi: 10.1007/s00259-007-0474-6. Epub 2007 Jun 13.
9
Theoretic criteria for antibody penetration into solid tumors and micrometastases.
J Nucl Med. 2007 Jun;48(6):995-9. doi: 10.2967/jnumed.106.037069. Epub 2007 May 15.
10
A designed ankyrin repeat protein evolved to picomolar affinity to Her2.
J Mol Biol. 2007 Jun 15;369(4):1015-28. doi: 10.1016/j.jmb.2007.03.028. Epub 2007 Mar 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验